Turn Therapeutics (NASDAQ:TTRX) Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Turn Therapeutics from “sell” to “hold.” Overall analyst sentiment is “Moderate Buy,” with an average price target of $9.00.
• Turn Therapeutics shares opened at $12.00, up 5.4%, with a market capitalization of approximately $357.5 million. The stock has traded between $2.57 and $16.45 over the past year.
• The company reported a quarterly loss of $0.20 per share, while analysts expect a full-year loss of $0.40 per share. Several institutional investors, including BlackRock and Ieq Capital, recently established positions.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research analysts also recently commented on TTRX. Zacks Research upgraded shares of Turn Therapeutics to a "hold" rating in a research report on Tuesday, July 21st. Lucid Cap Mkts raised Turn Therapeutics to a "strong-buy" rating in a report on Thursday, September 24th. WBB Securities reiterated a "sell" rating and issued a $10.00 price target on shares of Turn Therapeutics in a research note on Monday, September 14th. LADENBURG THALM/SH SH raised Turn Therapeutics to a "strong-buy" rating in a report on Monday, July 20th. Finally, Weiss Ratings downgraded Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $9.00.

Turn Therapeutics Trading Up 5.4%

Shares of Turn Therapeutics stock opened at $12.00 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $16.45. The company has a market capitalization of $357.48 million and a price-to-earnings ratio of -41.38. The firm's 50-day moving average price is $11.46 and its two-hundred day moving average price is $7.63.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. On average, analysts forecast that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Trading of Turn Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. bought a new stake in shares of Turn Therapeutics during the second quarter worth about $119,000. Bank of America Corp DE bought a new position in Turn Therapeutics in the 2nd quarter valued at approximately $103,000. Ieq Capital LLC acquired a new stake in Turn Therapeutics during the 2nd quarter worth approximately $1,660,000. BlackRock Inc. acquired a new stake in Turn Therapeutics during the 2nd quarter worth approximately $282,000. Finally, Bridgewater Advisors Inc. bought a new stake in Turn Therapeutics during the 2nd quarter worth approximately $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.